The emerging field of metabolomics has the potential to contribute significantly to biomarker discovery and cancer. While other techniques, such as DNA sequencing, have led to significant advances in precision oncology, metabolomics has yet to make its mark on the field.
New methods of using metabolomics as a tool for clinical cancer research and care were presented at the 2nd Annual Biomarker Conference by CureMatch, developer of a decision support platform for combination therapy in cancer.
See the full story at Oncology Central.
